Therapy with l-deprenyl (selegiline)
and relation to abuse liability
by
Schneider LS, Tariot PN, Goldstein B
Department of Psychiatry,
University of Southern California,
Los Angeles 90033.
Clin Pharmacol Ther 1994 Dec; 56(6 Pt 2):750-6

ABSTRACT

This article briefly reviews the clinical aspects and rationale for therapy with l-deprenyl for several neuropsychiatric conditions, including major depression, Alzheimer's disease, and Parkinson's disease. The rationale for the use of l-deprenyl in these conditions is discussed, and evidence for efficacy is reviewed. Lastly, there is a review of the lack of evidence for l-deprenyl's abuse potential and its use as putative nonspecific cognitive enhancer, a so-called "smart drug." Although l-deprenyl itself appears to have no abuse potential, it is theoretically possible that it might potentiate the actions and frequency of dosage and use of various drugs of abuse or dependence. This is as yet an underresearched area, and more work is required.

MAOIs
Review
Selegiline
Comparisons
Psychostimulant?
Selegiline N-oxide
Alzheimer's disease
Selegiline and MDMA
Selegiline pharmacology
Selegiline and nitric oxide
Amphetamine metabolites
Selegiline / neuroprotection
Selegiline and life-expectancy
Selegiline and methamphetamine
Selegiline as an immunostimulant
Selegiline enhances rodent erections
Dose-dependency of lifespan prolongation
Feb 2006: EMSAM (selegiline transdermal system) licensed by FDA

Refs
and further reading

HOME
HedWeb
Nootropics
cocaine.wiki
Future Opioids
BLTC Research
MDMA/Ecstasy
Superhapiness?
Utopian Surgery?
The Abolitionist Project
The Hedonistic Imperative
The Reproductive Revolution
Critique of Huxley's Brave New World

The Good Drug Guide
The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family